Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Pharvaris N.V. - Ordinary Shares (NQ:PHVS)

22.34 +0.12 (+0.54%)
Streaming Delayed Price Updated: 3:03 PM EST, Nov 3, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Pharvaris N.V. - Ordinary Shares

< Previous 1 2 3 4 5 6 Next >
PHVS Stock Earnings: Pharvaris Beats EPS for Q2 2024
PHVS stock results show that Pharvaris beat analyst estimates for earnings per share the second quarter of 2024. 
Via InvestorPlace
Pharvaris Reports Second Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Biogen Has Up To $10 Billion For Acquisitions; Why These Three Names Make Sense
Biogen has $8 billion to $10 billion in dry powder for acquisitions. Here are three names the company could examine. 
Via Investor's Business Daily
Pharvaris Announces Annual Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Analyst Expectations for Pharvaris's Future
 
Via Benzinga
Pharvaris Highlights Properties of Deucrictibant in Data Presentations at Recent Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Clinical and Nonclinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q1 2024
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the first quarter of 2024. 
Via InvestorPlace
Pharvaris Reports First Quarter 2024 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
PHVS Stock Earnings: Pharvaris Misses EPS for Q4 2023
PHVS stock results show that Pharvaris missed analyst estimates for earnings per share the fourth quarter of 2023. 
Via InvestorPlace
Pharvaris Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Appoints David Nassif, J.D., as Chief Financial Officer
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at the CIIC Spring 2024 Conference
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Phase 3 Clinical Study Design for Recently Initiated RAPIDe-3 Study, and Presents Quality-of-Life Improvement and Caregiver Behavior Data at Two Recent HAE Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present Deucrictibant Clinical Data at Upcoming Congresses
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Participate in the Leerink Global Biopharma Conference 2024
From Pharvaris N.V.
Via GlobeNewswire
Positive Results from CHAPTER-1 Phase 2 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks to be Presented at AAAAI 2024 Annual Meeting
Antagonism of the bradykinin B2 receptor via treatment with deucrictibant resulted in statistically significant reduction in rate of HAE attacks 
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Announces Extraordinary Meeting of Shareholders
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris to Present at the WSAAI Annual Meeting 2024
From Pharvaris N.V.
Via GlobeNewswire
Top-Notch Pharvaris Eyes Profit-Taking Zone On A Key FDA Decision
The company is working on a treatment for swelling attacks associated with a genetic disease. 
Via Investor's Business Daily
FDA Clears Pharvaris' Trial For Investigational Drug For Swollen Blood Vessels, Stock Jumps
Pharvaris receives FDA approval to advance deucrictibant for hereditary angioedema prophylaxis, lifting clinical hold. Learn about the latest developments in HAE treatment. 
Via Benzinga
Pharvaris Announces FDA Lifting of the Clinical Hold of Deucrictibant for the Prophylactic Treatment of HAE Attacks
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Provides Business Update and Outlines 2024 Strategic Priorities
From Pharvaris N.V.
Via GlobeNewswire
Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023
From Pharvaris N.V.
Via GlobeNewswire
Gold Moves Higher; Campbell Soup Earnings Top Expectations
U.S. stocks traded mixed toward the end of trading on Wednesday. The Dow traded up 0.05% to 36,143.40 while the NASDAQ fell 0.06% to 14,221.51. The S&P 500 also fell, dropping, 0.05% to 4,564.73. 
Via Benzinga
Topics Stocks
Why AeroVironment Shares Are Trading Lower By Over 9%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of AeroVironment, Inc. (NASDAQ: AVAV) moved lower during Wednesday’s session following second-quarter results. 
Via Benzinga
Turnaround For Pharvaris Since FDA Clinical Hold - Data Shows Its Oral Hereditary Angioedema Treatment Cuts Attacks
Pharvaris NV (NASDAQ: PHVS) released topline data from the CHAPTER-1 Phase 2 study meeting its primary endpoint, with deucrictibant demonstrating statistically significant and clinically meaningful... 
Via Benzinga
Crude Oil Down 4%; Pharvaris Shares Spike Higher
U.S. stocks traded mostly flat midway through trading, with the S&P 500 turning lower on Wednesday. The Dow traded up 0.01% to 36,126.75 while the NASDAQ rose 0.03% to 14,233.77. The S&P 500 also fell,... 
Via Benzinga
Topics Stocks
AMD Stock Alert: What to Expect From Advanced Micro Devices ‘Advancing AI’ Event
Advanced Micro Devices stock is climbing higher on Wednesday as AMD investors prepare for the company's Advancing AI event today. 
Via InvestorPlace
Topics Artificial Intelligence
THOR Industries Reports Upbeat Earnings, Joins Dave & Buster's Entertainment, Campbell Soup And Other Big Stocks Moving Higher On Wednesday
U.S. stocks traded higher, with the Dow Jones index gaining more than 50 points on Wednesday. 
Via Benzinga
Topics Stocks
< Previous 1 2 3 4 5 6 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.